PDF(Pubmed)
Abstract：
BACKGROUND: Decreased levels of circulating ethanolamine plasmalogens [PE(P)], and a concurrent increase in phosphatidylethanolamine (PE) are consistently reported in various cardiometabolic conditions. Here we devised, a plasmalogen score (Pls Score) that mirrors a metabolic signal that encompasses the levels of PE(P) and PE and captures the natural variation in circulating plasmalogens and perturbations in their metabolism associated with disease, diet, and lifestyle.
METHODS: We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial involving Shark Liver Oil (SLO) supplementation (n = 10, 100% men). We examined the association of the Pls Score with cardiometabolic risk factors, type 2 diabetes mellitus (T2DM), cardiovascular disease and all-cause mortality (over 17 years).
RESULTS: In a model, adjusted for age, sex and BMI, individuals in the top quintile of the Pls Score (Q5) relative to Q1 had an OR of 0.31 (95% CI 0.21-0.43), 0.39 (95% CI 0.25-0.61) and 0.42 (95% CI 0.30-0.57) for prevalent T2DM, incident T2DM and prevalent cardiovascular disease respectively, and a 34% lower mortality risk (HR = 0.66; 95% CI 0.56-0.78). Significant associations between diet and lifestyle habits and Pls Score exist and these were validated through dietary supplementation of SLO that resulted in a marked change in the Pls Score.
CONCLUSIONS: The Pls Score as a measure that captures the natural variation in circulating plasmalogens, was not only inversely related to cardiometabolic risk and all-cause mortality but also associate with diet and lifestyle. Our results support the potential utility of the Pls Score as a biomarker for metabolic health and its responsiveness to dietary interventions. Further research is warranted to explore the underlying mechanisms and optimise the practical implementation of the Pls Score in clinical and population settings.
BACKGROUND: National Health and Medical Research Council (NHMRC grant 233200), National Health and Medical Research Council of Australia (Project grant APP1101320), Health Promotion Foundation of Western Australia, and National Health and Medical Research Council of Australia Senior Research Fellowship (#1042095).
METHODS: We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial involving Shark Liver Oil (SLO) supplementation (n = 10, 100% men). We examined the association of the Pls Score with cardiometabolic risk factors, type 2 diabetes mellitus (T2DM), cardiovascular disease and all-cause mortality (over 17 years).
RESULTS: In a model, adjusted for age, sex and BMI, individuals in the top quintile of the Pls Score (Q5) relative to Q1 had an OR of 0.31 (95% CI 0.21-0.43), 0.39 (95% CI 0.25-0.61) and 0.42 (95% CI 0.30-0.57) for prevalent T2DM, incident T2DM and prevalent cardiovascular disease respectively, and a 34% lower mortality risk (HR = 0.66; 95% CI 0.56-0.78). Significant associations between diet and lifestyle habits and Pls Score exist and these were validated through dietary supplementation of SLO that resulted in a marked change in the Pls Score.
CONCLUSIONS: The Pls Score as a measure that captures the natural variation in circulating plasmalogens, was not only inversely related to cardiometabolic risk and all-cause mortality but also associate with diet and lifestyle. Our results support the potential utility of the Pls Score as a biomarker for metabolic health and its responsiveness to dietary interventions. Further research is warranted to explore the underlying mechanisms and optimise the practical implementation of the Pls Score in clinical and population settings.
BACKGROUND: National Health and Medical Research Council (NHMRC grant 233200), National Health and Medical Research Council of Australia (Project grant APP1101320), Health Promotion Foundation of Western Australia, and National Health and Medical Research Council of Australia Senior Research Fellowship (#1042095).
摘要：
背景：循环乙醇胺酶原[PE（P）]水平降低，在各种心脏代谢条件下，一直报道磷脂酰乙醇胺（PE）的同时增加。在这里我们设计了，aplasmaphenscore(Plsscore)，反映了一个代谢信号，包括PE(P)和PE的水平，并捕获循环中的自然变异，以及与疾病相关的代谢扰动，饮食，和生活方式。
方法：我们利用，来自澳大利亚肥胖症的血浆脂质，糖尿病和生活方式研究（AusDiab;n=10,339，55％女性），全国队列，设计Pls评分并在Busselton健康研究中验证(BHS；n=4,492，56%女性，血清脂凝素）和一项安慰剂对照交叉试验，其中包括补充鲨鱼肝油（SLO）（n=10，100％男性）。我们检查了Pls评分与心脏代谢危险因素的关联，2型糖尿病（T2DM），心血管疾病和全因死亡率（超过17岁）。
结果：在模型中，根据年龄调整，性别和BMI，相对于Q1，Pls评分（Q5）前五分之一的个体的OR为0.31（95%CI0.21-0.43），普遍的T2DM为0.39（95%CI0.25-0.61）和0.42（95%CI0.30-0.57），分别为2型糖尿病和心血管疾病,死亡率风险降低34%(HR=0.66;95%CI0.56-0.78)。饮食和生活习惯与Pls评分之间存在显着关联，并且通过SLO的饮食补充来验证这些关联，从而导致Pls评分的显着变化。
结论：Pls评分作为捕获循环疟原虫自然变异的量度，不仅与心脏代谢风险和全因死亡率呈负相关,而且与饮食和生活方式相关.我们的结果支持Pls评分作为代谢健康及其对饮食干预反应的生物标志物的潜在效用。有必要进行进一步的研究，以探索潜在的机制并优化Pls评分在临床和人群环境中的实际实施。
背景：国家卫生与医学研究委员会（NHMRC资助233200），澳大利亚国家卫生和医学研究委员会（项目拨款APP1101320），西澳大利亚州健康促进基金会，澳大利亚国家卫生和医学研究委员会高级研究奖学金(#1042095)。
方法：我们利用，来自澳大利亚肥胖症的血浆脂质，糖尿病和生活方式研究（AusDiab;n=10,339，55％女性），全国队列，设计Pls评分并在Busselton健康研究中验证(BHS；n=4,492，56%女性，血清脂凝素）和一项安慰剂对照交叉试验，其中包括补充鲨鱼肝油（SLO）（n=10，100％男性）。我们检查了Pls评分与心脏代谢危险因素的关联，2型糖尿病（T2DM），心血管疾病和全因死亡率（超过17岁）。
结果：在模型中，根据年龄调整，性别和BMI，相对于Q1，Pls评分（Q5）前五分之一的个体的OR为0.31（95%CI0.21-0.43），普遍的T2DM为0.39（95%CI0.25-0.61）和0.42（95%CI0.30-0.57），分别为2型糖尿病和心血管疾病,死亡率风险降低34%(HR=0.66;95%CI0.56-0.78)。饮食和生活习惯与Pls评分之间存在显着关联，并且通过SLO的饮食补充来验证这些关联，从而导致Pls评分的显着变化。
结论：Pls评分作为捕获循环疟原虫自然变异的量度，不仅与心脏代谢风险和全因死亡率呈负相关,而且与饮食和生活方式相关.我们的结果支持Pls评分作为代谢健康及其对饮食干预反应的生物标志物的潜在效用。有必要进行进一步的研究，以探索潜在的机制并优化Pls评分在临床和人群环境中的实际实施。
背景：国家卫生与医学研究委员会（NHMRC资助233200），澳大利亚国家卫生和医学研究委员会（项目拨款APP1101320），西澳大利亚州健康促进基金会，澳大利亚国家卫生和医学研究委员会高级研究奖学金(#1042095)。
